published meta-analysis   sensitivity analysis   studies

Cannabidiol in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias recoverydetailed resultsCrippa (CANDIDATE), 2021 0.54 [0.15; 1.94] 0.54[0.15; 1.94]Crippa (CANDIDATE), 202110%91NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-28 10:13 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 1234 - roots T: 290